Atara posts Q1 net loss of $74.8M; R&D head and CTO to depart in May/June

Atara Biotherapeutics, Inc.

2023-Q1 EPS reported -$0.72 revenue$1,226,000

Net loss of $74.8M ($0.72/sh) vs $88.1M ($0.87/sh) in Q1 2022; cash $205.4M, runway into Q2 2024.
Jakob Dupont (EVP Global R&D) resigns effective May 12, 2023; Charlene Banard (CTO) departs June 9, 2023.
Tab-cel BLA discussions with FDA continue; label expansion data expected Q4 2023.
ATA188 Phase 2 EMBOLD primary data readout on track for October 2023.
ATA3219 IND filing for B-cell malignancies anticipated end of Q2 2023.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Charlene Banard

Executive Vice President, Chief Technical Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2023-06-09
Filed: May 8, 2023, 7:59 PM ET

Charlene Banard, the Company’s Executive Vice President, Chief Technical Officer, will depart the Company effective as of June 9, 2023

Departed

Jakob Dupont

Executive Vice President, Global Head of Research and Development

ATRA · Atara Biotherapeutics, Inc.

Effective: 2023-05-12
Filed: May 8, 2023, 7:59 PM ET

Jakob Dupont, M.D., the Company’s Executive Vice President, Global Head of Research and Development, on May 5, 2023, notified the Company of his intention to resign from the Company effective as of May 12, 2023

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Atara Biotherapeutics, Inc. reported the first quarter 2023 results: net income net losses of $74.8 million, EPS $0.72 per share.

Period: the first quarter 2023
Net income: net losses of $74.8 million
EPS: $0.72 per share
Result: reported results

Exact text from the filing

Atara reported net losses of $74.8 million, or $0.72 per share for the first quarter 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Charlene Banard departed as Executive Vice President, Chief Technical Officer at Atara Biotherapeutics, Inc..

Action: depart
Role: Executive Vice President, Chief Technical Officer

Exact text from the filing

Charlene Banard, the Company’s Executive Vice President, Chief Technical Officer, will depart the Company effective as of June 9, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jakob Dupont resigned as Executive Vice President, Global Head of Research and Development at Atara Biotherapeutics, Inc..

Action: resigned
Role: Executive Vice President, Global Head of Research and Development

Exact text from the filing

Jakob Dupont, M.D., the Company’s Executive Vice President, Global Head of Research and Development, on May 5, 2023, notified the Company of his intention to resign from the Company effective as of May 12, 2023

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-018793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.